|
Match
|
Document |
Document Title |
|
|
US20140221484 |
GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and... |
|
|
US20130295173 |
COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS
The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present... |
|
|
US20110052694 |
USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES
Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and... |
|
|
US20090221620 |
GENTIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF
The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to... |
|
|
US20080015209 |
COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and... |
|
|
US20070160666 |
Pharmaceutical formulation
The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline... |
|
|
US20070093527 |
Methods for treating disorders associated with hyperlipidemia in a mammal
The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for... |
|
|
US20060211762 |
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or... |
|
|
US20060193887 |
Medical devices having nanoporous bonding layers
The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices... |
|
|
US20060003002 |
Pharmaceutical compositions with synchronized solubilizer release
Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug... |
|
|
US20160068466 |
ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein,... |
|
|
US20130030051 |
GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial... |
|
|
US20100104651 |
Pharmaceutical Compositions Containing Diacerein
A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such... |
|
|
US20060211763 |
Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
A pharmaceutical composition in unit dose form, comprising an essentially homogeneous solution comprising a statin essentially dissolved in solvent system comprising natural or synthetic omega-3... |
|
|
US20060189582 |
Compositions and methods for treatment of disorders of protein aggregation
The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in... |
|
|
US20060105050 |
Compositions comprising fenofibrate and simvastatin
The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor simvastatin or... |
|
|
US20050272054 |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and... |
|
|
US20050026992 |
Treatment and prevention of cardiovascular events
A pharmaceutical dosage form for treating or preventing cardiovascular events comprises therapeutic amounts of: a β-adrenergic receptor antagonist, a diuretic, or both; a cholesterol-lowering... |
|
|
US20170096386 |
Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions... |
|
|
US20160108473 |
GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular... |
|
|
US20150252013 |
TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE
Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen... |
|
|
US20120014883 |
Compositions Comprising Derivatives Of Essential Oil Compounds And Use In Personal Care Products
Compositions containing one or more derivatives of essential oil compounds for use in personal care compositions, such as compositions for oral, throat and skin care are disclosed. These... |
|
|
US20110269735 |
GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular... |
|
|
US20070027093 |
Anorectic
The present invention relates to an anorectic containing a compound having a DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrug thereof or a pharmaceutically acceptable salt thereof... |
|
|
US20060068015 |
Solid dosage form comprising a fibrate and a statin
The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a... |
|
|
US20050209128 |
Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients... |
|
|
US20050065121 |
Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
It has been discovered that certain selected probucol monoesters, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds... |
|
|
US20050059720 |
Medicinal compositions for the prevention or treatment of cardiac failure
The present invention relates to pharmaceutical compositions, which contain a HMG-CoA reductase inhibitor selected from the group consisting of pravastatin, simvastatin, lovastatin, pitavastatin... |
|
|
US20050019398 |
Flashmelt oral dosage formulation
There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination... |
|
|
US20120003198 |
Lutein/Zeaxanthin for glare protection
The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye... |
|
|
US20080113934 |
USE OF DIPYRIDAMOLE OR MOPIDAMOL FOR TREATMENT AND PREVENTION OF FIBRIN-DEPENDENT MICROCIRCULATION DISORDERS
A method of treatment of the human or non-human animal body for treating fibrin-dependent microcirculation disorders is disclosed, for example, microcirculation disorders caused by metabolic... |
|
|
US20070185057 |
Novel Indanone Compounds
Novel indanylidene compounds can be used as UV-A filters in cosmetic compositions for protecting skin and hair and for technical applications. |
|
|
US20050096296 |
Pharmaceutical compositions with synchronized solubilizer release
Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug... |
|
|
US20160089355 |
COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT
Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular... |
|
|
US20140235714 |
CANCER THERAPY
The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic... |
|
|
US20140235605 |
GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular... |
|
|
US20140171490 |
Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful... |
|
|
US20140072550 |
GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection,... |
|
|
US20110064712 |
Dietary Supplement Compositions and Methods of Making and Using the Same
Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed. |
|
|
US20090264497 |
STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-COA REDUCTASE INHIBITOR
Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The... |
|
|
US20070191467 |
STATIN AND OMEGA-3 FATTY ACIDS FOR LIPID THERAPY
A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level... |
|
|
US20070105894 |
Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor
The invention relates to a combination of at least two therapeutic combination components selected from the group consisting of (i) an AT1-receptor antagonist or an AT1 receptor antagonist... |
|
|
US20060025469 |
Methods for decreasing beta amyloid protein
Blood cholesterol levels are correlated with production of amyloid β protein (Aβ), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be... |
|
|
US20050287210 |
Sustained release L-arginine formulations and methods of manufacture and use
The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in... |
|
|
US20050277691 |
Pravastatin pharmaceutical formulations and methods of their use
The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present... |
|
|
US20050256053 |
Combined use of a GLP-1 compound and another drug for treating dyslipidemia
Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug. |
|
|
US20050124641 |
Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
A process is provided for preparing chiral diol sulfones of the structure where R3 is preferably where R4a is preferably aryl such as phenyl, and R1a is preferably alkyl such as t-butyl, which are... |
|
|
US20050038007 |
Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
A dosage form comprises a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the... |
|
|
US20070135376 |
METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE MITOCHONDRIAL EFFICIENCY
Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain... |
|
|
US20070031493 |
Pharmaceutical compositions
The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said... |